Corona Remedies Ltd IPO

Corona Remedies Limited is an India-focused branded pharmaceutical formulation company engaged in developing, manufacturing, and marketing products across women’s healthcare, cardio-diabeto, pain management, urology, and other therapeutic areas. According to the Industry Report, they were the second fastest-growing company among the top 30 in the Indian Pharmaceutical Market (IPM) in domestic sales between MAT December 2021 and MAT December 2024. During this period, their domestic sales grew at a CAGR of 19.90%, more than 2.25 times the IPM’s growth of 8.79%. Their diversified product portfolio comprises 67 brands across therapeutic areas including women’s healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals (VMN, gastrointestinal, and respiratory) as of December 31, 2024. They have a proven track record of building and scaling brands, reflected in a core portfolio of 27 “engine” brands, which contributed 72.99% of domestic sales during MAT December 2024.